No abstract

Background and purpose: Cranial irradiation is associated with significant neurocognitive sequelae, secondary to radiation-induced damage to hippocampal cells. It has been shown that hippocampal-sparing (HS) leads to modest benefit in neurocognitive function in patients with brain metastases, but further improvement is possible. We hypothesized that improved benefits could be seen using HS in patients treated with stereotactic radiation (HS-SRS). Our study evaluated whether the hippocampal dose could be significantly reduced in the treatment of brain metastases using SRS, while maintaining target coverage. Materials and methods: Sixty SRS plans were re-planned to minimize dose to the hippocampus while maintaining target coverage. Patients with metastases within 5 mm of the hippocampus were excluded. Minimum, mean, maximum and dose to 40% (mean equivalent dose in 2 Gy per fraction, EQD 2 to the hippocampus) were compared between SRS and HS-SRS plans. Median number of brain metastases was two. Results: Compared to baseline SRS plans, hippocampal-sparing plans demonstrated D min was reduced by 35%, from 0.4 Gy to 0.3 Gy (p-value 0.02). Similarly, D max was reduced by 55%, from 8.2 Gy to 3.6 Gy, D mean by 52%, from 1.6 Gy to 0.5 Gy, and D 40 by 50%, from 1.8 Gy to 0.9 Gy (p-values <0.001). Conclusions: Our study demonstrated that further reduction of hippocampal doses of more than 50% is possible in the treatment of brain metastases with SRS using dose optimization. This could result in significantly improved neurocognitive outcomes for patients treated for brain metastases.

No abstract

No abstract

No abstract